0.54
-0.2601(-32.51%)
Currency In USD
| Previous Close | 0.8 |
| Open | 0.8 |
| Day High | 0.81 |
| Day Low | 0.52 |
| 52-Week High | 0.84 |
| 52-Week Low | 0.26 |
| Volume | 1.81M |
| Average Volume | 723,709 |
| Market Cap | 127.26M |
| PE | -2.41 |
| EPS | -0.22 |
| Moving Average 50 Days | 0.38 |
| Moving Average 200 Days | 0.4 |
| Change | -0.27 |
If you invested $1000 in Vaxart, Inc. (VXRT) 10 years ago, it would be worth $28.37 as of January 13, 2026 at a share price of $0.54. Whereas If you bought $1000 worth of Vaxart, Inc. (VXRT) shares 5 years ago, it would be worth $79.63 as of January 13, 2026 at a share price of $0.54.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026
GlobeNewswire Inc.
Jan 08, 2026 9:01 PM GMT
SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart or “the Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, to
Vaxart to Host Upcoming Conference Calls
GlobeNewswire Inc.
Nov 07, 2025 1:00 PM GMT
Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Va
Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025
GlobeNewswire Inc.
Oct 20, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today anno